692739-25-6

Basic information

• Product Name: 6-Maleimidocaproic acid-PFP ester
• Synonyms: 6-Maleimidocaproic acid-PFP ester
• CAS NO: 692739-25-6
• Molecular Formula: C₁₆H₁₂F₅NO₄
• Molecular Weight: 377.262796
• Mol File: 692739-25-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Maleimidocaproic acid-PFP ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Maleimidocaproic acid-PFP ester(692739-25-6)
• EPA Substance Registry System: 6-Maleimidocaproic acid-PFP ester(692739-25-6)

Safety Data

• Hazardous Substances Data: 692739-25-6(Hazardous Substances Data)

Usage

Description

6-Maleimidocaproic acid PFP ester contains a maleimide and PFP ester end group. Maleimides react with thiol groups within the pH range of 6.5 to 7.5 and form stable thioester bonds. PFP is an activated ester which can react with amine groups to form stable amide bonds.

Upstream product

• 108-31-6 maleic anhydride 
• 60-32-2 6-aminohexanoic acid 
• 55750-53-3 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid 
• 771-61-9 2,3,4,5,6-pentafluorophenol 

Downstream Products

• 159857-80-4 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide 
• 1639351-92-0 N-((S)-1-(((S)-1-((4-(chloromethyl)phenyl)amino)-1-oxo-5-ureidopentan- 2-yl)amino)-3-methyl-1-oxobutan-2-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide 
• 692739-27-8 pentafluorophenyl 6-(6-(6-maleimidohexanamido)hexanamido)hexanoate 
• 692739-26-7 6-[6-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-hexanoylamino]-hexanoic acid pentafluorophenyl ester 

Relevant articles and documents

Studies on heterobifunctional cross-linking reagents, 6-maleimidohexanoic acid active esters

6-Maleimidohexanoic acid N-hydroxysuccinimide ester has been used widely for preparation of enzyme immunoconjugates as a unique heterobifunctional cross-linking reagent. Its heterobifunctional reactivity is good, but its ester portion hydrolyzes easily in

COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS

The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.